APM - Earnings announcements

Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. "Our team and Yoov have spent considerable time and effort on the due diligence process, the negotiation of definitive terms, and the preparation of necessary transactional and listing documentation. However, current market conditions have introduced significant uncertainty regarding the availability of the required funding for the transaction. After careful consideration, our Board ha

Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. "During the first half of 2023, we remained focused on advancing the development of our therapeutic programs. We continue to work towards advancing our ALS-4 and SACT-1 clinical programs and our PathsDx liquid biopsy program through potential collaborations. In light of the macroeconomic environment, we remain vigilant at controlling costs and resources of the company whilst continuing

ORLANDO, FL / ACCESSWIRE / March 17, 2023 / RedChip Companies will air new interviews with Aptorum Group Limited (NASDAQ:APM, PARIS:APM) and ASP Isotopes Inc. (NASDAQ:ASPI) on The RedChip Money Report® on Bloomberg TV, this Saturday, March 18, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aptorum Group Limited (NASDAQ:APM): https://www.aptoruminfo.com/interview_accessASP Isotopes Inc. (NASDAQ:ASPI): https://aspiinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years

ORLANDO, FL / ACCESSWIRE / November 25, 2022 / RedChip Companies will air a new interview Aptorum Group Limited (NASDAQ:APM)(PARIS:APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, on The RedChip Money Report® on Bloomberg TV, this Saturday, November 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Aptorum's CEO and Executive Chairman Darren Lui discusses the Company's pipeline for oncology, autoimmune, and infectious diseases, a $15 billion market opportunity, the comp

Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2022. "During the first half of 2022, we remained focused on advancing the development of our therapeutic programs. As announced in early 2022, both our SACT-1 program (targeting neuroblastoma) and ALS-4 program (targeting MRSA), has announced the completion and positive Phase I clinical trial results. Our RPIDD program (liquid biopsy based approach to infectious

ORLANDO, FL / ACCESSWIRE / September 23, 2022 / RedChip Companies will air an interview on Aptorum Group Limited (NASDAQ:APM)(PARIS:APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, on The RedChip Money Report® on Bloomberg TV, this Saturday, September 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Aptorum's CEO Darren Lui discusses the development and commercialization of their novel therapeutics, their diagnostic product, their granted U.S. patents, and much more.Ac

NEW YORK, NY and LONDON, UK, and PARIS, FRANCE / ACCESSWIRE / August 19, 2022 / RedChip Companies will air an interview on Aptorum Group Limited (NASDAQ:APM, PARIS:APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, on The RedChip Money Report® on Bloomberg TV, this Saturday, August 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Aptorum's CEO Darren Lui discusses the development and commercialization of their novel therapeutics, their diagnostic product, their granted U.

Regulatory News: Aptorum Group Limited (NASDAQ:APM, Euronext Paris: APM))) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2021. "During the first half of 2021, we remained focused on advancing the development of our therapeutic programs. As announced in early 2021, our ALS-4 program (targeting infections caused by Staphylococcus aureus including MRSA) commenced a Phase 1 clinical study in Canada. We are pleased that 5 total cohorts, which represent the essential part of the single as